Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Investigational treatment for ulcerative colitis (UC) and Crohn’s disease (CD) has Marketing Authorisation Application submitted

Takeda Pharmaceutical Company Limited (“Takeda”) today announced that a Marketing Authorisation Application (MAA) has been submitted to The European Medicines Agency (EMA) for vedolizumab, an investigational, gut-selective humanized monoclonal antibody for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn’s disease (CD), the two most common types of inflammatory bowel disease (IBD).

8 Mar 2013

University of Manchester leads systems medicine research network for inflammatory bowel disease

The University of Manchester is leading a €12 million systems medicine research network to identify better treatments for Inflammatory Bowel Disease like Crohn's Disease.

6 Mar 2013

SIRT1 gene may be involved in development of type 1 diabetes

A JDRF-funded study out of Switzerland has shown that a single gene called SIRT1 may be involved in the development of type 1 diabetes (T1D) and other autoimmune diseases. The study, "Identification of a SIRT1 Mutation in a Family with Type 1 Diabetes," was published today in Cell Metabolism and represents the first demonstration of a monogenetic defect leading to the onset of T1D.

6 Mar 2013

No increased risk for inflammatory bowel disease with isotretinoin

Researchers report no link between isotretinoin use for the treatment of acne and increased risk for inflammatory bowel disease in women of reproductive age.

1 Mar 2013

EpiCept fourth quarter revenue decreases to $0.1 million

EpiCept Corporation today announced operating and financial results for the fourth quarter and full year ended December 31, 2012, and provided an update on the Company's merger with Immune Pharmaceuticals, Ltd. (Immune).

28 Feb 2013

Scientists identify two populations of human cells that migrate to the intestine

Researchers at Wake Forest Baptist Medical Center and colleagues have identified a special population of adult stem cells in bone marrow that have the natural ability to migrate to the intestine and produce intestinal cells, suggesting their potential to restore healthy tissue in patients with inflammatory bowel disease (IBD).

28 Feb 2013

Avaxia initiates AVX-470 Phase 1b clinical study in ulcerative colitis

Avaxia Biologics, Inc., a clinical-stage biopharmaceutical company developing gut-targeted therapeutics, announced today that the first patient has been dosed in a Phase 1b clinical study of AVX-470, an oral anti-TNF antibody, for the treatment of ulcerative colitis.

25 Feb 2013

Immune Pharmaceuticals commences Phase II study with bertilimumab to treat ulcerative colitis

Immune Pharmaceuticals Ltd., a privately held Israeli company, and EpiCept Corporation announced today that Immune is initiating, following authorization from Israeli health authorities, a Phase II double-blind placebo controlled study with its lead drug, bertilimumab, in patients with moderate-to-severe ulcerative colitis.

21 Feb 2013

Santarus launches UCERIS for induction of remission in patients with ulcerative colitis

Santarus, Inc. announced today the U.S. commercial launch of UCERIS (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis.

14 Feb 2013

Research sheds light on how E. coli thrive in the intestine of people with IBD

Scientists have long puzzled over why "bad" bacteria such as E. coli can thrive in the guts of those with inflammatory bowel disease (IBD), causing serious diarrhea. Now UC Davis researchers have discovered the answer-one that may be the first step toward finding new and better treatments for IBD.

10 Feb 2013

DRCRF announces recipients of Nov. 2012 Damon Runyon Fellows

The Damon Runyon Cancer Research Foundation, a non-profit organization focused on supporting innovative early career researchers, named 15 new Damon Runyon Fellows at its fall Fellowship Award Committee review.

29 Jan 2013

Simple urine test picks up mesalamine non-adherence

A readily available urine test could identify ulcerative colitis patients who are non-adherent to their mesalamine therapy, research shows.

25 Jan 2013

Intestinal bacteria can produce biochemicals and hormones that stop development of diabetes

All humans have enormous numbers of bacteria and other micro-organisms (10 to 14) in the lower intestine. In fact our bodies contain about ten times more bacteria than our own cells and these tiny passengers are extremely important for our health. They help us digest our food and provide us with energy and vitamins.

19 Jan 2013

FDA approves Santarus’ UCERIS for induction of remission in patients with ulcerative colitis

Santarus, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved UCERIS (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis.

16 Jan 2013

Ulcerative colitis impairs work capacity

Patients with ulcerative colitis have higher rates of sick leave or disability pension than the general population, show findings published in Gastroenterology.

28 Dec 2012

Scientists discover how Yersinia pestis avoids setting off immune system's early infection-alarm

The plague-causing bacteria Yersinia pestis evades detection and establishes a stronghold without setting off the body's early alarms.

14 Dec 2012

Colectomy fails to ease ulcerative colitis sick leave burden

Patients with ulcerative colitis take more time off work than the general population, even after undergoing colectomy, shows a large Swedish study.

13 Dec 2012

UCB directs national effort to educate public about Crohn's disease

In recognition of Crohn's and Colitis Awareness Week (December 1-7), UCB, Inc. is directing a national effort to educate the public about Crohn's disease and inspire those living with the condition to speak out about it.

1 Dec 2012

Ginger.io announces $6.5M Series A funding

Ginger.io, the behavioral health analytics startup, today announced a $6.5 million Series A funding round led by Khosla Ventures.

29 Nov 2012

FDA clears Avaxia’s AVX-470 IND for treatment of ulcerative colitis

Avaxia Biologics, Inc., a privately-held biotechnology company developing oral antibody drugs that act locally within the digestive tract, announced today that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for AVX-470 for the treatment of ulcerative colitis.

27 Nov 2012

Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Investigational treatment for ulcerative colitis (UC) and Crohn’s disease (CD) has Marketing Authorisation Application submitted

University of Manchester leads systems medicine research network for inflammatory bowel disease

SIRT1 gene may be involved in development of type 1 diabetes

No increased risk for inflammatory bowel disease with isotretinoin

EpiCept fourth quarter revenue decreases to $0.1 million

Scientists identify two populations of human cells that migrate to the intestine

Avaxia initiates AVX-470 Phase 1b clinical study in ulcerative colitis

Immune Pharmaceuticals commences Phase II study with bertilimumab to treat ulcerative colitis

Santarus launches UCERIS for induction of remission in patients with ulcerative colitis

Research sheds light on how E. coli thrive in the intestine of people with IBD

DRCRF announces recipients of Nov. 2012 Damon Runyon Fellows

Simple urine test picks up mesalamine non-adherence

Intestinal bacteria can produce biochemicals and hormones that stop development of diabetes

FDA approves Santarus’ UCERIS for induction of remission in patients with ulcerative colitis

Ulcerative colitis impairs work capacity

Scientists discover how Yersinia pestis avoids setting off immune system's early infection-alarm

Colectomy fails to ease ulcerative colitis sick leave burden

UCB directs national effort to educate public about Crohn's disease

Ginger.io announces $6.5M Series A funding

FDA clears Avaxia’s AVX-470 IND for treatment of ulcerative colitis

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Ulcerative Colitis News and Research

Latest Ulcerative Colitis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in